Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD
The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
"We're reducing the burden on sites, patients, and sponsors by sparing unnecessary PET scans and lumbar punctures."
Several Alzheimer disease (AD) trials screen and exclude a substantial number of potential patients who do not meet study criteria relating to amyloid pathology consistent with AD. The phase 2 ALTITUDE-AD (NCT06335173) trial is an 80-week, global, randomized, double-blind, placebo-controlled, multi-site study of sabirnetug (Acumen Pharmaceuticals) in patients with early AD and evidence of amyloid pathology. The screening occurs in 2 parts, with the first screening part being a blood test using the Fujirebio plasma p-tau217 assay. Then, patients with p-tau217 concentrations of at least 0.15 pg/mL are eligible for the second screening part, which is a confirmatory test of amyloid pathology.
New data presented from the ongoing trial showed that more than half of potential study participants were excluded because of a plasma p-tau217 test result less than 0.15 pg/mL.1,2 Authors noted that participants who proceeded to amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ42/40 were enriched for meeting amyloid-based inclusion criteria. Therefore, the p-tau217 enrichment strategy appeared to be performing as intended, reducing unnecessary amyloid PET scans or LP procedures for potential clinical trial participants compared with previous methods.
These new results were presented at the
REFERENCES
1. Feaster T, et al. ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer's Disease. Presented at: 2024 CTAD; October 29-November 1; Madrid, Spain. LB11.
2. Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference. News Release. Acumen Pharmaceuticals. Published October 23, 2024. Accessed October 31, 2024. https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-deliver-late-breaking-presentation-17th
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025